Update on Insulin Management in Type 2 Diabetes
- Joshua J. Neumiller, PharmD, CDE, CGP, FASCP,
- Peggy Soule Odegard, BS, PharmD, BCPS, CDE, FASCP and
- Carol H. Wysham, MD
Abstract
In Brief
This article provides a brief overview of the various insulin products currently available on the market and discusses considerations regarding insulin therapy in people with type 2 diabetes. Issues involving the initiation, titration, and optimization of insulin therapy to meet individual patient treatment goals are discussed.
Footnotes
-
Joshua J. Neumiller, PharmD, CDE, CGP, FASCP, is an assistant professor, and Carol H. Wysham, MD, is an adjunct professor in the Department of Pharmacotherapy, College of Pharmacy at Washington State University in Spokane. Dr. Wysham is also a clinical endocrinologist for Rockwood Clinic in Spokane. Peggy Soule Odegard, BS, PharmD, BCPS, CDE, FASCP, is an associate professor and director of the geriatrics program at the University of Washington School of Pharmacy and a clinical pharmacist and diabetes educator at the University of Washington Department of Medicine in Seattle. She is also an associate editor of Diabetes Spectrum.
-
Note of disclosure: Dr. Wysham has received honoraria for speaking engagements from Sanofi-Aventis, Novo Nordisk, and Eli Lilly and Co., all of which are manufacturers of insulin products for the treatment of diabetes.
- American Diabetes Association(R) Inc., 2009
